Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. - Wikidata - wikimedia - TriplyDB

Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.

Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.

http://www.wikidata.org/entity/Q53980487

about

Treatment for IgG and IgA paraproteinaemic neuropathy Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies Treatment for IgG and IgA paraproteinaemic neuropathy Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS).Treatment of chronic inflammatory demyelinating polyneuropathy.Clinical spectrum of chronic acquired demyelinating polyneuropathies.Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis Chronic dysimmune neuropathies: Beyond chronic demyelinating polyradiculoneuropathy.Immunotherapy of idiopathic inflammatory neuropathies.Successful treatment of IgM paraproteinaemic neuropathy with fludarabine A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy.Axonal neuropathy associated with monoclonal gammopathy of undetermined significance.Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy.Predicting treatment response in chronic, acquired demyelinating neuropathies.Evidence-based treatment of chronic immune-mediated neuropathies.Treatment in inflammatory neuropathies.An update on monoclonal gammopathy and neuropathy.Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.Paraproteinemic Neuropathy.Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies.Paraproteinemic neuropathy.Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance.Rituximab therapy in monoclonal IgM-related neuropathies

P2860

Q24187168-7152FE84-129B-4CDA-B528-396FC4A5B7D8 Q24197877-4BDE8DCC-ACA4-42E1-8E4F-FF5993CB5DC6 Q24243918-FC5464F8-B839-4291-B377-B0B55E4DD97F Q24246371-6539E3AD-985A-40A9-B7D2-C8DE3E8585CF Q24250235-39E5C43C-329C-4488-901C-2E8375D2A008 Q28216546-17BAC84D-9B39-4FC1-B9F1-68E56E501142 Q33252356-771555CE-D633-4C30-9EB3-0E3653C9835D Q33762563-67D14B40-6F53-401E-A12C-554A172EE240 Q33996087-2918511F-4BF5-428E-BF01-F0AF359FBEF0 Q34251202-74CD1FBD-67F0-4E1D-A04F-45B55846BBBC Q34922742-EDD8D45B-FFE5-4E9D-A524-89E89DF7E630 Q35121614-1225A618-6A6B-48BA-AC45-9AB94B359567 Q35203389-BB2B4C60-573E-4457-BAAC-F8404A0DB924 Q35451247-65A7EE61-4863-43A1-93C2-9F3394B61EFE Q36150688-5CF7AC25-1DF6-4E06-8725-06A72F7B95EA Q36316949-0D142810-64BC-4941-A43A-E62DF50B9303 Q36607310-45E33A17-015F-4917-9449-55F5B3CFCCBF Q36641529-DF23AAA6-D266-4848-A457-11F48BF0CE40 Q37550515-10E324A2-7404-4AEC-AEB0-0C4A7C428323 Q37733512-8D3A51A2-CAB7-447A-AAD3-7CD8376A9989 Q37957050-61A55239-8E3C-44FC-B5DC-49B0885CFA31 Q38856824-4C1BFF44-5931-41B1-97AD-6515B4A30D50 Q38971983-9CED3A5F-1C32-4769-831C-1A22FDD70492 Q39422508-FACC420F-8B12-40FB-9693-66E74DDCD634 Q45036396-466B8EBD-A65B-4DC1-9CA7-48F8DED2D3F2 Q50242655-C77160DF-AEB4-4275-9375-2B316EF201FC Q53791232-2E67E191-9403-4058-8B66-3C181D01B4A9 Q53965800-D62403A1-6CCA-40CA-BF97-6B2F5926A405 Q57904868-F8FEA70F-6132-4AE0-9763-F116CC0B1C0F

P2860

Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.

http://www.wikidata.org/entity/Q53980487

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

1996年學術文章

@zh

1996年學術文章

@zh-hant

name

Intermittent cyclophosphamide ...... of undetermined significance.

@en

Intermittent cyclophosphamide ...... of undetermined significance.

@nl

type

label

Intermittent cyclophosphamide ...... of undetermined significance.

@en

Intermittent cyclophosphamide ...... of undetermined significance.

@nl

prefLabel

Intermittent cyclophosphamide ...... of undetermined significance.

@en

Intermittent cyclophosphamide ...... of undetermined significance.

@nl

P1433

Q53980487-A235F2E8-35EC-4EB8-8D24-568174271146

P1476

Q53980487-99B4CD7D-3DCE-4CF2-BE9A-D906F07BB9E3

P2093

Q53980487-5F79A36C-F759-4105-91E8-DD2AC6049A97

Q53980487-A9A03DE4-5A3F-4DFA-BFF6-2832A306FBCE

Q53980487-B37F711A-9CBC-4E49-98EE-F795B54D7AD5

Q53980487-B6A37E88-7B66-43DB-9A23-F1E58174E862

Q53980487-D943CD8F-59D4-466E-BA91-DA9803B3A4FE

Q53980487-E3786AD7-5E4F-4B85-A982-B4EFD6693BC0

Q53980487-E6D7BEA8-6FDE-449F-80FD-90A1D91065AE

Q53980487-EA7404D2-C138-4387-9316-D7D9440F3D1E

P304

Q53980487-6CA7E076-5626-4F31-B2A4-7CE8DFB26F27

P31

Q53980487-8C5DE978-0155-4B39-A272-937A055D8690

P356

Q53980487-C8FB4441-9D07-4061-BB45-000AF63B9D58

P407

Q53980487-64603F87-D017-4D62-B063-82E5DEB071EA

P433

Q53980487-D2C4B45F-88BD-418D-96E9-1D03654CAFDF

P478

Q53980487-AF8F1D58-5907-444B-9836-BBFA8F2AFFF9

P577

Q53980487-54CF5B39-92B5-4445-997B-1E76D8911D82

P698

Q53980487-1A2FA3A2-7383-467D-BC66-A466C98F189D

P356

P1433

P1476

Intermittent cyclophosphamide ...... of undetermined significance.

@en

P2093

Franssen H

http://www.w3.org/2001/XMLSchema#string

Jennekens FG

http://www.w3.org/2001/XMLSchema#string

Lokhorst HM

http://www.w3.org/2001/XMLSchema#string

Notermans NC

http://www.w3.org/2001/XMLSchema#string

Teunissen LL

http://www.w3.org/2001/XMLSchema#string

Van den Berg LH

http://www.w3.org/2001/XMLSchema#string

Van der Graaf Y

http://www.w3.org/2001/XMLSchema#string

Wokke JH

http://www.w3.org/2001/XMLSchema#string

P304

1227-1233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.47.5.1227

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

1996-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8909434

http://www.w3.org/2001/XMLSchema#string